CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment
CERo Therapeutics reported a clinical update from its Phase 1 CERTAIN-T trial for CER-1236, noting that six patients have now been treated with no dose-limiting toxicities observed. Patient five, who had refractory acute myeloid leukemia, saw bone marrow blast counts drop from baseline to 7% by Day 42, enabling an allogeneic stem cell transplant on Day 71.
Key figures
- Drug Name
- CER-1236
- Phase Of Trial
- Phase 1
- Dose patient 5
- 4 million cells/kg
- Transplant day
- 71
- Next cohort dose
- 1 billion cells/patient
- Patients treated
- 6
- Blast count day 14
- 14%
- Blast count day 28
- 14%
- Blast count day 42
- 7%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.